

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTION PASSED AT THE 8TH BOARD MEETING FOR FY2022

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Company had, on 18 October 2022, issued a notice of board meeting to its directors in respect of the 8th board meeting for the financial year ending 31 December 2022 (“FY2022”), and the board meeting was duly convened by means of live meeting and telephone conference on 28 October 2022. The said meeting was convened in compliance with the applicable Companies Law, Securities Law and the Articles of Association of the Company, and the following resolutions were discussed and passed by the 7 directors out of the full board of 7 directors:

1. That, the full text and summary of the third quarter financial statement for FY2022 prepared in accordance with the accounting standards of the People's Republic of China and the International Financial Reporting Standards, be approved.

To the best knowledge of the directors and the management of the Company, there are no other information that would cause the contents of the aforesaid financial statement to be false or misleading.

2. That, the proposed adjustments to the internal management structure of the Company, be approved.

The number of the operation and management departments of the Company headquarters is proposed to be adjusted from 14 to 12 (the “**Proposed Adjustment**”). The internal management structure of the Company following the Proposed Adjustment will be as follows:

- (1) Securities and Investment Department (Office of the Board of Directors) (证券与投资部 (董事会办公室));
- (2) General Manager's Office (总经理办公室);
- (3) Strategic Management Department (战略管理部);
- (4) Medicinal Materials Resources Centre (药材资源中心);
- (5) Intelligent Manufacturing Centre (智能制造中心);
- (6) Finance Centre (财务中心);
- (7) Human Resources Centre (人力资源中心);
- (8) Quality Management Department (质量管理部);
- (9) Environment, Health and Safety Department (EHS 部);
- (10) Product Planning Department (产品规划部);
- (11) Digital and IT Department (数字与 IT 部); and
- (12) Audit Department (审计部).

3. That, the proposed appointment of Mr. WANG Jian (王健) as the Company's representative of securities affairs, be approved.

Ms. XIE Xi (谢希) no longer serves as the Company's representative of securities affairs due to change of job.

Mr. WANG Jian (王健), born in 1992, holds a master's degree and has obtained the qualification of secretary to the board of directors of listed companies (上市公司董事会秘书资格), national legal profession qualification (国家法律职业资格), qualification for practising in securities industry (证券从业资格) and certificate of accounting profession (会计从业资格). Since July 2018, Mr. Wang has been responsible for the work relating to the Company's investor relations.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
28 October 2022